Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan

Background In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels. Methods This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Tria...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2009, Vol.157 (1), p.91-96
Main Authors: Belonje, Anne M.S., MD, Westenbrink, B. Daan, MD, Voors, Adriaan A., MD, PhD, Haehling, Stephan von, MD, Ponikowski, Pjotr, MD, PhD, Anker, Stefan D., MD, PhD, van Veldhuisen, Dirk J., MD, PhD, Dickstein, Kenneth, MD, PhD
Format: Article
Language:English
Subjects:
Age
Aged
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological and medical sciences
Captopril - therapeutic use
Cardiology. Vascular system
Cardiovascular
Coronary heart disease
Erythropoietin - blood
Female
Gender
Heart
Heart attacks
Heart failure
Heart Failure - blood
Heart Failure - drug therapy
Heart Failure - etiology
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Humans
Kidney diseases
Ligands
Losartan - therapeutic use
Male
Medical prognosis
Medical sciences
Mortality
Myocardial Infarction - blood
Myocardial Infarction - complications
Myocarditis. Cardiomyopathies
Prognosis
Regression analysis
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels. Methods This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure. We investigated the determinants and the prognostic role of elevated Epo levels in these patients, and we studied the change in Epo levels by either captopril or losartan. Results The correlation between Epo and hemoglobin at baseline ( r = 0.348, P < .001) and after 1 month ( r = 0.272, P  
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2008.08.020